Evidence map›Paper›PMID 34921830›Full record

ArticleNeuropharmacology2022

A limited access oral oxycodone paradigm produces physical dependence and mesocorticolimbic region-dependent increases in DeltaFosB expression without preference.

Vishakh Iyer, Taylor J Woodward, Romario Pacheco, Andrea G Hohmann

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Negative allosteric modulation of CBNeuropharmacology · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Investigating the potential of mirtazapine to induce drug-seeking behavior in free-choice drinking mouse model.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Article
  12. Negative allosteric modulation of CBPharmacological research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Vishakh IyerProgram in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.
Taylor J WoodwardProgram in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.
Romario PachecoDepartment of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.
Andrea G HohmannProgram in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA; Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA. Electronic address: hohmanna@indiana.edu.
Indiana University Bloomington · US

Funding

INTEGRATIVE PREDOCTORAL TRAINING IN DRUG ABUSE RESEARCH AT INDIANA UNIVERSITYT32DA024628 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI Andrea Grace Hohmann, Kenneth Mackie · 2008 to 2026
$3.1M
CB2 Cannabinoid Mechanisms for Suppressing Opioid Tolerance and DependenceR01DA047858 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI HOHMANN, ANDREA GRACE, MACKIE, KENNETH · 2019 to 2023
$2.6M
Role of CB2 in Analgesic MechanismsR01DA041229 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI HOHMANN, ANDREA GRACE, MACKIE, KENNETH · 2016 to 2020
$1.8M
A Novel Mechanism for Decreasing Opioid RewardR21DA042584 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI HOHMANN, ANDREA GRACE, REBEC, GEORGE VINCENT · 2016 to 2017
$392k
NIDA NIH HHS R01 DA041229NIDA NIH HHS R01 DA047858NIDA NIH HHS R21 DA042584NIDA NIH HHS T32 DA024628
6 · The paper itself

Abstract

The abuse of oral formulations of prescription opioids has precipitated the current opioid epidemic. We developed an oral oxycodone consumption model consisting of a limited access (4 h) two-bottle choice drinking in the dark (TBC-DID) paradigm and quantified dependence with naloxone challenge using mice of both sexes. We also assessed neurobiological correlates of withdrawal and dependence elicited via oral oxycodone consumption using immunohistochemistry for DeltaFosB (ΔFosB), a transcription factor described as a molecular marker for drug addiction. Neither sex developed a preference for the oxycodone bottle, irrespective of oxycodone concentration, bottle position or prior water restriction. Mice that volitionally consumed oxycodone exhibited hyperlocomotion in an open field test and supraspinal but not spinally-mediated antinociception. Both sexes also developed robust, dose-dependent levels of opioid withdrawal that was precipitated by the opioid antagonist naloxone. Oral oxycodone consumption followed by naloxone challenge led to mesocorticolimbic region-dependent increases in the number of ΔFosB expressing cells. Naloxone-precipitated withdrawal jumps, but not the oxycodone bottle % preference, was positively correlated with the number of ΔFosB expressing cells specifically in the nucleus accumbens shell. Thus, limited access oral consumption of oxycodone produced physical dependence and increased ΔFosB expression despite the absence of opioid preference. Our TBC-DID paradigm allows for the study of oral opioid consumption in a simple, high-throughput manner and elucidates the underlying neurobiological substrates that accompany opioid-induced physical dependence.

Indexed as

Opioid-Related DisordersSubstance Withdrawal SyndromeAnalgesics, OpioidAnimalsBehavior, AnimalDisease Models, AnimalLocomotionMiceNaloxoneNarcotic AntagonistsNociceptionNucleus AccumbensOxycodoneProto-Oncogene Proteins c-fosAnalgesics, OpioidFosb protein, mouseNaloxoneNarcotic AntagonistsOxycodoneProto-Oncogene Proteins c-fosDependenceMouseOral self-administrationOxycodonePrescription opioidWithdrawal

Identifiers

PMID34921830
PMCPMC8817207
OpenAlexW4200584533

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.